A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationJohn T. Brandt, Kenneth J. Winters, Christopher D. Payne et al.|American Heart Journal|2006Cited by 571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseTomas Jernberg, Lars Wallentin, Christopher D. Payne et al.|European Heart Journal|2006Cited by 537
Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet ProfileJoseph A. Jakubowski, Lars Wallentin, Kenneth J. Winters et al.|Cardiovascular Drug Reviews|2007Cited by 249
A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y<sub>12</sub> inhibitor, compared with clopidogrel in healthy humansJoseph A. Jakubowski, Kenneth J. Winters, Stephen Freestone et al.|British Journal of Clinical Pharmacology|2006Cited by 128
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A single ascending dose study in healthy humansFumitoshi Asai, Kenneth J. Winters, Joseph A. Jakubowski et al.|Platelets|2006Cited by 108